Immucell (IUL) AI Stock Analysis
Immucell
(Frankfurt:IUL)
No summary available
Immucell (IUL) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 93.18M
- Dividend Yield
- ―
- Average Volume (3M)
- 77
- Price to Earnings (P/E)
- 121.3
- Beta (1Y)
- 0.86
- Revenue Growth
- 0.79%
- EPS Growth
- -58.57%
- Country
- Germany
- Employees
- 73
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immucell Business Overview & Revenue Model
Company Description
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market...
Immucell Earnings Call Summary
The call highlighted meaningful commercial momentum: double-digit product revenue growth (Q2 +11.5%, H1 +20.9%), strong U.S. performance and expanding market share, improved profitability and adjusted EBITDA, and a clearly defined multi‑phase capacity expansion to more than triple production capacity. Offsetting these positives were significant gross margin pressure driven by lower manufacturing output, a recurring cost shift from the discontinued Re-Tain program into COGS, a one-time scrap event (~$150K), and a sharp decline in international sales (–38.9% in Q2). Management presented concrete mitigation steps (yield improvement initiatives, capacity investments, colostrum sourcing programs) and expects to finance most expansion with cash on hand. Overall, the positives (revenue, profitability, working capital strength, and actionable expansion plans) appear to outweigh the operational and margin headwinds, though execution risk remains on manufacturing yields and international ramp.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance from the call focused on materially expanding and de‑risking supply while improving costs and yields: management plans an ~ $8.0M, two‑phase capacity program (a $3.5M freeze‑drying phase to be completed in H1 2027 and ~ $4.5M liquids phase targeted by year‑end 2027) that it expects will more than triple current capacity, shorten processing time from 2–3 months to under 1 month, and improve long‑term product cost; the company is on track to produce nearly 1.0 million more manufacturing units in 2026 versus 2025, financing the majority with cash on hand ($8.9M as of 6/30/26) and operating cash (may use credit line), while continuing yield work (colostrum is ~50% of product cost). Recent operating/financial context cited with that guidance: Q1 production exceeded 450,000 units/month and Q2 averaged ~350,000 units/month (seasonal/planned), Q2 product sales $7.2M (+11.5% YoY) and H1 product sales $17.5M (+20.9% YoY), gross margin 33.9% (vs 43.7% LY) with an 11.1‑point sequential decline driven ~7.5 points by lower output, 2.1 points by ~$150k scrap and 1.9 points by the Re‑Tain cost shift, adjusted EBITDA of $2.7M in Q2 and $5.4M for H1 (both include a $2M legal settlement), net income of $1.8M ($0.20/share) in Q2 and $3.8M for H1, inventory $9.1M and working capital $16.6M, distributor out‑the‑door volumes +21% Q1 / +28% Q2 (24% H1), and U.S. market share for First Defense rising from ~15% in Dec‑2025 to ~19% in June‑2026 (share of spend ~29% to ~38%).
Immucell Risk Analysis
Immucell disclosed 38 risk factors in its most recent earnings report. Immucell reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksImmucell Peers Comparison
Overall Rating
INO49Neutral
PDSB47Neutral
ARCT43Neutral
RANI42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| INO | 49Neutral | $62.29M | -0.52 | -1005.80% | ― | -100.00% | 54.89% |
| PDSB | 47Neutral | $151.21M | -2.25 | -708.20% | ― | ― | 30.16% |
| ARCT | 43Neutral | $313.51M | -3.31 | -46.54% | ― | -82.95% | -49.04% |
| RANI | 42Neutral | $82.24M | -2.19 | -129.93% | ― | 306.42% | 70.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:IUL | Immucell | 9.15 | 3.85 | 72.64% | |
| INO | Inovio Pharmaceuticals | 0.60 | -1.90 | -75.92% | |
| ARCT | Arcturus Therapeutics | 11.03 | 1.73 | 18.60% | |
| XBIT | XBiotech Inc. | 1.88 | -0.41 | -17.90% | |
| PDSB | Pds Biotechnology | 1.44 | 0.51 | 54.18% | |
| RANI | Rani Therapeutics Holdings, Inc. Class A | 0.59 | -1.56 | -72.56% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.